The FDA had approved Diclegis as the only treatment for nausea and vomiting of pregnancy (NVP) when conservative management fails.
Duchesnay USA chief executive officer Gilbert Godin said Diclegis will become an treatment option for healthcare professionals caring for pregnant women with NVP.
"The product’s safety profile and its proven clinical effectiveness make it a convenient and innovative treatment for women who are seeking effective NVP-symptom relief," Godin added.
Pregnancy Category A status attained by the NVP therapy indicates the results of controlled studies that have not demonstrated an increased risk to an unborn baby.